These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23027454)

  • 41. Is antiarrhythmic treatment in the elderly different? a review of the specific changes.
    Deneer VH; van Hemel NM
    Drugs Aging; 2011 Aug; 28(8):617-33. PubMed ID: 21812498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome.
    van Opstal JM; Schoenmakers M; Verduyn SC; de Groot SH; Leunissen JD; van Der Hulst FF; Molenschot MM; Wellens HJ; Vos MA
    Circulation; 2001 Nov; 104(22):2722-7. PubMed ID: 11723026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
    Singh BN; Wadhani N
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of cardiac arrhythmias during pregnancy: safety considerations.
    Joglar JA; Page RL
    Drug Saf; 1999 Jan; 20(1):85-94. PubMed ID: 9935279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiarrhythmic drugs and torsade de pointes.
    Lazzara R
    Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients.
    McCauley M; Vallabhajosyula S; Darbar D
    Card Electrophysiol Clin; 2016 Jun; 8(2):481-93. PubMed ID: 27261836
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Gender differences on physiological function test].
    Nakagawa M
    Nihon Rinsho; 2015 Apr; 73(4):601-5. PubMed ID: 25936147
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Brugada and long QT-3 syndromes: two phenotypes of the sodium channel disease.
    Khan IA; Nair CK
    Ann Noninvasive Electrocardiol; 2004 Jul; 9(3):280-9. PubMed ID: 15245345
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular biology and cellular mechanisms of Brugada and long QT syndromes in infants and young children.
    Antzelevitch C
    J Electrocardiol; 2001; 34 Suppl():177-81. PubMed ID: 11781953
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Experimental arrhythmia models. Critical study of correlations with arrhythmias observed in clinical practice].
    Dupuis BA; Vincent AC
    Arch Mal Coeur Vaiss; 1981 Dec; 74 Spec No():17-27. PubMed ID: 6803699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The pro-arrhythmic effects of anti-arrhythmia agents].
    Haverkamp W; Wichter T; Chen X; Hördt M; Willems S; Rotman B; Hindricks G; Kottkamp H; Borggrefe M; Breithardt G
    Z Kardiol; 1994; 83 Suppl 5():75-85. PubMed ID: 7846949
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can antiarrhythmic drugs survive survival trials?
    Pratt CM; Waldo AL; Camm AJ
    Am J Cardiol; 1998 Mar; 81(6A):24D-34D. PubMed ID: 9537220
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients.
    Kay GN; Plumb VJ; Arciniegas JG; Henthorn RW; Waldo AL
    J Am Coll Cardiol; 1983 Nov; 2(5):806-17. PubMed ID: 6630761
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Arrhythmias in the congenital long QT syndrome: how often is torsade de pointes pause dependent?
    Viskin S; Fish R; Zeltser D; Belhassen B; Heller K; Brosh D; Laniado S; Barron HV
    Heart; 2000 Jun; 83(6):661-6. PubMed ID: 10814624
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacologic management of arrhythmias in patients with congenital heart disease.
    Batra AS; Luna CF; Silka MJ
    Am J Cardiovasc Drugs; 2001; 1(2):91-103. PubMed ID: 14728039
    [TBL] [Abstract][Full Text] [Related]  

  • 57. What should we expect from the next generation of antiarrhythmic drugs?
    Camm AJ; Yap YG
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):307-17. PubMed ID: 10090237
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical characteristics and management of proarrhythmias during antiarrhythmic therapy].
    Kobayashi Y
    Nihon Rinsho; 2013 Jan; 71(1):79-85. PubMed ID: 23631176
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Electro-Mechanical window: a risk marker for Torsade de Pointes in a canine model of drug induced arrhythmias.
    van der Linde HJ; Van Deuren B; Somers Y; Loenders B; Towart R; Gallacher DJ
    Br J Pharmacol; 2010 Dec; 161(7):1444-54. PubMed ID: 21054337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
    Singh BN
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.